The scientific founders and advisors of Evox are world-leading exosome scientists and physicians, with expertise in all aspects from exosome biology and purification to targeted drug delivery systems and treatment of rare life-threatening diseases.
Dr Antonin de Fougerolles
Chief Executive Officer
Tony has over 20 years’ experience in the pharmaceutical and biotechnology industry. He has a strong background in successfully developing and advancing multiple different transformative therapeutic drug platforms in both the nucleic acid and biologics space. In addition, his in-depth expertise in drug development has led to the progression of multiple assets through clinical trials, as well as playing a key role in the negotiation of major partnerships. Prior to joining Evox Therapeutics, Tony was CSO at Ablynx NV and Moderna Therapeutics, and VP Research at Alnylam Pharmaceuticals. Ph.D. in Immunology from Harvard University.
Dr Per Lundin
Co-Founder and Chief Operating Officer
Per has over 10 years of experience advising, founding and leading biotech companies developing groundbreaking therapies. Per co-founded Evox and has acted as the company’s COO since inception. Prior to Evox, Per co-founded and served as CEO of IsletOne Therapeutics, a clinical stage cell therapy company. Previously, Per managed a European business development channel for Thomson Reuters and prior to that qualified as a European Patent Attorney in the biotech practice of one of the largest European IP law firms. He started his career as a Research Scientist. Per earned his Ph.D. at the Karolinska Institute, holds an MSc in Biotechnology Engineering, and an MBA.
Dr David Virley
Head of Research
David has over 20 years experience in the bio-pharmaceutical and R&D industry. He has expertise in advancing neuroscience-based programs to the clinic, for a range of CNS disorders. In addition, his in-depth expertise in drug development has led to the progression of multiple assets through clinical trials, as well as playing a key role in the negotiation of major partnerships. Prior to joining Evox Therapeutics, David was Head of Pharmacology at AbbVie in Germany, and also worked at GlaxoSmithKline (GSK) for 10 years. David is a Pharmacologist/Neuroscientist by training, obtaining his Ph.D. from the Institute of Psychiatry at King’s College London.
VP Process Development
Bo has over 30 years’ experience in the biotechnology industry. He has expertise in the development of CMC for wide range of protein, viral vector and cell therapy medicinal products. His deep knowledge of the technical, regulatory and commercial issues faced at each stage of process and product development has led to the progression of multiple assets from preclinical development through to commercial launch. Prior to joining Evox Therapeutics, Bo was Head Process Development, Cell Gene Therapy at GSK, Head R+D at Fujifilm and Head Process Development at AZ and holds a BSc/MSc in Biochemistry/Biotechnology.
Vice President Business Development
Simon has 20+ years’ experience in pharmaceutical Business Development,
Product Portfolio Strategy and operational experience in international markets.
He was previously VP Corporate Strategy at Gyroscope Therapeutics and held
leadership roles at Astellas. Simon is currently Board advisor to Sunstone Capital.